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Introduction
Hepatocellular carcinoma [HCC] is the fifth most frequent 
malignancy in women and the seventh in men worldwide [1] and 
in about 80-85% of cases arises in a cirrhotic liver. Early diagnosis 
is mandatory to improve the prognosis of this tumour and the 
regular application of surveillance protocol is absolutely relevant 
in high- risk populations. Cirrhosis is considered the major risk 
factor for developing HCC [2]. Moreover, male sex, older age, 
advanced Child Pugh class, viral and alcoholic etiologies have 
been consistently associated with HCC in different studies [3,4]. 
Transjugular intrahepatic portosystemic shunt
[TIPS] is an established procedure for the treatment of portal 
hypertension complications. The largest body of evidence 
supports its application in recurrent or refractory variceal 
bleeding and refractory ascites. Its use has also been advocated 
for acute variceal bleeding, hepatic hydrothorax, and hepatorenal 
syndrome. With the replacement of bare metal stents with 
polytetrafluoroethylene-covered stents, shunt patency has 
improved dramatically, thus, improving outcomes. However, to 
date, although TIPS significantly reduces the portal pressure and 
the recurrence of its complications, it doesn’t improve survival of 
cirrhotic patients [5]. TIPS placement may induce hypoxic injury 
by either totally or partially diverting portal venous blood flow 
directly into systemic circulation. This reduction of parenchymal 
oxygenation may be involved in hepatocarcinogenesis through 
the activation of hepatic stellate cells [6]. Futhermore, TIPS could 
influence the outcome and safety of loco-regional treatment 
for HCC, as a result of the portal blood diversion following the 
stentinsertion. Until now very few papers have been written 
about a possible “interaction” between TIPS and HCC. Therefore, 
whether TIPS and HCC are “Friends or Foes” is still an ongoing 
dilemma.
Incidence of HCC in TIPS Bearing 
Patients: A Relationship Still Hidden in 
the Fog 
A possible role of porto - systemic shunt in the development of 
hepatocellular carcinoma [HCC] was described for the first time in 
a post-mortem histological study published in the earliest 80’s [7], 
which reported an increased prevalence of primary liver cancer 
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after surgical porto-caval shunt. However, another cohort study 
didn’t confirm this finding [8]. Currently, the most important 
porto-systemic shunt is represented by TIPS, whose application 
in the treatment of complication of portal hypertension has 
become a mainstay [9]. As a consequence, a possible impact on 
the development of HCC could lead to the application of more 
intensive surveillance protocol.
In 2008, Banares et al., suggested an association between the 
onset of HCC and the placement of TIPS in a case – control 
retrospective study [10]. However, the majority of patients 
enrolled in the TIPS cohort was Child-Pugh C and the possible 
impact of a more severe liver disease on the higher incidence 
of HCCcould be postulated. Two subsequent experiences didn’t 
confirmed these data: the prospective study by Libbrecth et al. 
[11] and our case-control study [12] were concordant in showing 
a similar incidence of primary liver cancer in cirrhotics with and 
without TIPS. In particular, our study design was very similar to 
the one by Banares et al. but patients’ selection was more careful 
and the proportion of patients with advanced liver disease and 
classifiable as Child-Pugh C was very low.
The development of liver cancer nodules was similar in cirrhotics 
with and without TIPS, although in stent bearing patients the onset 
time of HCC was briefer. Moreover, tumour diameter was slightly 
larger in TIPS patients and the localization was more frequent in 
the right lobe (Table 1). Although these data seem to suggest a 
possible relationship between TIPS and hepatocarcinogenesis, 
we concluded that in TIPS bearing patients without severe liver 
disease the application of more strict protocols of surveillance 
is not indicated; as such, the finding of a similar neoplastic 
disease stage at diagnosis of HCC in both groups seems to 
strongly support this idea and suggests that a similar chance of 
treatment could be offered in these patients without any change 
in surveillance intervals. Recently, another retrospective study 
[13] failed to confirm an association between TIPS insertion and 
HCC, but, interestingly, revealed an increased prevalence of liver 
dysplasia in patients with patent stent. Of note, the rate of small 
cell dysplasia, which is a precancerous lesion [14], was similar 
between patients with and without TIPS, while large cell dysplasia, 
whose role in HCC is still unclear, was more frequent in cirrhotic 
with inhabitant stent, maybe as a consequence of the histological 
locoregional modifications arising in liver parenchyma following 
TIPS placement. However, these results need to be interpreted 
cautiously because the short time of observation [12.1 months] 
could have influenced the negative outcome of the study. Overall, 
what few data exist are controversial and, currently, a clear role 
of TIPS in the development of hepatocellular carcinoma cannot 
be stated [15-22]. Therefore, there is no strict recommendation 
for shortening the surveillance interval in TIPS bearing patients.
Chronicle of a Problematic 
Relationship: TIPS and HCC from a 
Clinical Point of View 
There are two different clinical settings in which a possible 
interaction between TIPS and HCC may be suggested. On one 
side, there are cirrhotic patients who underwent TIPS placement 
to treat complications of clinically significant portal hypertension 
[CSPH] and developed HCC during follow up [23,24].
On the other side, there are patients with an established diagnosis 
of HCC who developed refractory ascites or experienced recurrent 
bleeding episodes, thus becoming potential candidates for TIPS. 
These two scenarios put the physician in front of different clinical 
problems [25-29]. In the first case the question is: “How could TIPS 
interfere with the outcome of HCC treatment and the developing 
of metastasis? In the second case, we would ask: 1] How could HCC 
interfere with safety and technical feasibility of TIPS insertion? 2] 
Could TIPS make radical treatment [surgery], otherwise excluded 
for the presence of CSPH, feasible? 3] Could TIPS be an efficient 
bridge for liver transplant candidates? 4] Could TIPS be an 
efficient option in patients with advanced liver cancer [BCLC C 
and D]? Very few data have been described and to the best of our 
knowledge, all the papers about this topic are retrospective and 
included a small size population [30-36]. In following sessions we 
will discuss more carefully the key points mentioned above. In 
particular, with regard to the possible interference between TIPS 
and HCC treatment, no data exist about a possible role of TIPS 
insertion before surgical resection. Therefore, our attention will 
be focused on the outcome of locoregional treatment.
TIPS and HCC: Influence on 
Locoregional Treatments
To the best of our knowledge there are no published series about 
the possible role of TIPS in the treatment of portal hypertension 
in potential surgery candidates, but we can speculate that 
patients with well-preserved liver function excluded from surgery 
for CSPH, according to the BCLC staging system [37], may benefit 
from stent insertion before surgical resection. Only one paper 
described the “interaction” between TIPS and ablative treatment 
in comparison to TACE without any conclusion regarding the 
influence of stent insertion on treatment choice and outcome 
[38]. Not surprisingly a large part of the interest has been focused 
on transarterial locoregional treatments [TLR]. Due to decreased 
portal blood flow after TIPS placement, it may be suggested that 
TLR in patients with patent stent may result in increased tissue 
ischemia. Moreover, the onset of arterioportal shunt following 
TIPS insertion may decrease LTR efficacy. In spite of these 
considerations, literature about the application of transarterial 
treatment in TIPS patients is poor [several case series and only 
two case control studies]. In particular, of the published studies 
([38-46]; Table 2) only two [38,39] described hepatotoxicity and 
the efficacy of SIRT while the rest are all focused on TACE. Overall, 
there is little data available; in fact, in all papers the populations 
enrolled are very small [from 5 to 20 pts]. Therefore the results 
need to be interpreted cautiously. Futhermore, although some 
case series reported a satisfactory safety profile for TACE in TIPS 
patients [39,40] two subsequent studies [40,41] didn’t confirm 
this conclusion.
In particular, the series reported by Kohi et al. [42] represented 
the only case-control study regarding TACE hepatotoxicity in 
patients with [10 pts] and without stent [148 pts]. The majority 
of patients were BCLC A stage in both groups [TIPS group- 50 % 
vs. 52%- non TIPS group; p=0.97]. In this paper, 70 % of patients 
in the TIPS group experienced one or more hepatobiliary serious 
adverse events [SAE] versus 36 % in non-TIPS group [p=0.46]. 
Among the hepatobiliary SAEs documented, only the onset of 
grade 3 or 4 hyperbilirubinemia differs significantly between the 
two groups [60 % in TIPS group vs. 20 % in non-TIPS group; p 
3© Under License of Creative Commons Attribution 3.0 License
ARCHIVOS DE MEDICINA
ISSN 1698-9465
2016
Vol. 2 No. 1: 23
Journal of Imaging and Interventional Radiology
information doesn’t exist to support this recommendation. Apart 
from the experience of few case reports, only five papers focused 
their attention on the technical feasibility and the safety profile 
of TIPS in patients previously diagnosed with HCC ([47-49]; Table 
3). In the small case series [5 pts] of Sakaguchi et al. [39], the 
application of TIPS for the treatment of portal hypertension 
complication in the setting of HCC patients was described for 
the first time. The technical feasibility of TIPS insertion was 100 
% and none of the patients developed severe adverse events. 
In all of them the stent was located far from the tumor. The 
rate of stent dysfunction was high [20%], although observation 
time was very short. This finding may probably be related to 
the application of bare stents rather than any influence of HCC. 
With regard to survival, the time of observation was too short 
for the assessment of this endpoint. In 2003, the experience of 
Wallace et al., described the placement of TIPS through primary 
and secondary liver neoplasm in nine patients [cirrhotic and non-
cirrhotic] with refractory ascites or recurrent bleeding. Similarly 
to what has been described by Sakaguchi et al., technical success 
was achieved in 100 % of cases and nobody developed life-
threatening events after stent implantation.
However, also in this case, only bare stents were used and the 
rate of TIPS dysfunction was high [33%] within 15 days from the 
procedure. Median overall survival [OS] was of only 229 days and, 
of note, two deaths occurred within 30 days of TIPS placement. 
Potential thoracic metastases were identified in two patients 
during follow up, but none of them had a preprocedural CT 
scan of chest. Therefore this data can’t be correctly evaluated. 
Lowest rates of technical success of TIPS implantation [71%] were 
described in the series byJiang et al. [49], but this was the first 
experience which included patients with portal cavernoma. After 
ten years of “literary silence”, the study by Liu et al. Published 
in 2014, represented one of the most important papers on this 
topic for the following reasons: 1] The observed population was 
the largest ever described in literature - 58 pts 2] all patients were 
affected by advanced HCC [35 with HCC stage C and 23 stage D 
accordingly to BCLC staging System] and portal vein thrombosis 
or cavernoma. Although the success rate of TIPS placement was 
100 %, five patients in these studies experienced tumour rupture 
after stent insertion, contrary to previous reports. In two cases 
the intraabdominal hemorrhage was fatal. It’s not clear whether 
or not, in these patients, the stent traversed the tumour, but 
we have to take into account that the extension of neoplastic 
disease was larger than in the previous reports. In particular, in 
patients who developed adverse events, the tumour burden was 
more than 10 cm. Moreover, the prognosis was very poor with 
a median survival of 77 days and restenting was necessary in 
twelve patients [21%] because of the onset of a TIPS dysfunction. 
Subsequently, Bettinger et al. Reports another series of 40 pts 
with successful implantation of TIPS. No severe complications 
were observed after stent placement and the overall survival 
was 180 days; also in this case patient’s selection wasn’t careful 
including BCLC D patients [20%]. Eight patients [20%] experienced 
TIPS dysfunction, only one case being related to tumoral invasion 
of the stent 
Taken together, these data seem to suggest that, although TIPS 
is feasible in patients with HCC, its placement should be carefully 
evaluated case by case. In particular, in patients with advanced 
= 0.009] although it was equally reversible in both. The rate of 
irreversible SAE was overlapping in the two cohorts. Of course 
this study has some limitations. In addition to its retrospective 
nature, the large difference in the number of patients enrolled in 
the groups [10 vs. 148] may have limited the power to detect small 
differences. Moreover, given that the rate of liver transplantation 
within on 1 year was significantly higher in the TIPS group with 
respect to the non-TIPS group, the possible impact of TACE 
related hepatotoxicity on overall survival [OS] in stent bearing 
patients is not evaluable. Taken together these data suggest 
that, although TACE hepatotoxicity seems to be increased in TIPS 
patients, this treatment may be convenient in patients who are 
candidates for OLT and require adequate control of neoplastic 
disease as a bridge to liver transplantation. But in patients who 
are not candidates for OLT, to establish whether or not TACE may 
be a convenient approach is difficult because data are lacking. 
Therefore, clinical good sense has a pivotal role and the careful 
selection of candidates is mandatory in these cases. From this 
point of view, in stent bearing patients with HCC, TACE should 
be reserved to those with a very well preserved liver function 
only if a superselective/selective approach is possible. These 
suggestions are more important if we consider that the number 
of TACE session required to achieve an objective response is 
higher than in patients without stent, as reported by Kuo et al. 
[43]. This experience
represented the only case- control study about the efficacy 
of TACE in TIPS versus non TIPS patients and reports a greater 
number of patients requiring additional treatment after a first 
session of TACE in the TIPS group, although not significantly 
(40% vs. 26 %-non TIPS; p=0.4). Although this data doesn’t 
seem encouraging, the time to progression was overlapping 
between the groups, but, also in this case, the higher rate of liver 
transplantation in TIPS group may have influenced this result.
Risk of Spreading and Lung 
Dissemination after Tips Insertion
One reason for being particularly cautious when proposing TIPS 
in HCC patients is the fear related to the possibility of the tumour 
spreading as the stent may traverse malignant tissue, especially 
in centrally located nodules. To date, only two papers have 
investigated pulmonary spreading after TIPS insertion [44-47] 
in patients with HCC with controversial results as the lack of a 
control group and the short observation time makes the results 
difficult to interpret. In the paper of Bettinger et al., only one 
patient developed lung metastasis 7 years after HCC diagnosis 
and 6 years after TIPS insertion. In this patient the tumour was 
not centrally located and TIPS was positioned away from the 
neoplastic lesion. Liu et al reported the onset of lung metastases 
in 7 pts; no differences were observed between patients with 
intratumoral stent and patients with stent far from the tumor. But 
this data is probably influenced by a very short median survival 
[77 days]. Moreover, about half of patients died within 30 days of 
TIPS placement. Therefore, whether or not TIPS is a real risk factor 
for the development of lung dissemination remains uncertain. 
Technical Feasibility and Safety Profile
Primary hepatic malignancy is considered a relative 
contraindication for TIPS placement although relevant 
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or end-stage HCC who are not candidate for liver transplantation, 
TIPS insertion may be not indicated for the following reasons: on 
one side, the poor cancer-related survival and, on the other side, 
the willingness to preserve the best quality of life [QoL] possible 
minimizing the morbidity related to invasive procedure. In fact, 
the onset of hepatic encephalopathy and also, the high rate of 
TIPS dysfunction, could lead to an important increase of the 
hospitalization rate, thus worsening the QoL. Therefore, in BCLC 
C and D patients, TIPS placement may only add management cost 
without improving prognosis. In addition, although a certain role 
of TIPS placement cannot be demonstrated, the safety profile 
of this procedure seems to be reduced in patients with large 
neoplastic disease and as a consequence, TIPS should be avoided 
in this setting.
Conclusions
Although some speculations about a possible role of TIPS in the 
development of hepatocarcinogenesis may be suggested, the 
clinical experience doesn’t confirm a higher incidence of HCC 
in stent bearing patients: to date, only one paper confirms this 
association and three studies are contrary. Therefore, in these 
patients, there are not sufficient reasons for suggesting any 
change in surveillance for the detection of early HCC. In patients 
with an established diagnosis of HCC and CSPH, TIPS placement 
may hypothetically facilitate the access to surgery; however, data 
are still lacking. Prospective studies are required to verify whether 
or not surgery following the correction of portal hypertension by 
stent insertion is effective as in elective ideal candidates. On the 
contrary, in patients with advanced hepatocellular carcinoma, 
TIPS doesn’t seem to have any role in the treatment of portal 
hypertension complications as it may worse the quality of life in 
a clinical setting characterized by poor survival. With regard to 
TACE, its efficacy seems to be reduced in patients with a patent 
stent, maybe as a consequence of the onset of arterioportal shunt 
following the TIPS placement; therefore more sessions of TACE 
are required in these patients to achieve an adequate neoplastic 
disease control. In addition, TACE seems to be less safe in patients 
with stent because it may worse liver function; as a consequence, 
it should be performed preferably in patients awaiting for liver 
transplantation. In conclusion, what is the answer to the initial 
question? Are TIPS and hepatocellular carcinoma friends or foes? 
It depends!
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